Systemic sclerosis & Raynaud's
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis
Main finding · ILD developmentResult — go to the resultHazard ratio 1.13 95% CI 0.93–1.38Authors' conclusion
Our findings did not confirm a preventive role of early initiation of immunosuppressive therapy vs late initiation on ILD development.
Study context
- Population
- Adults with systemic sclerosis (SSc) starting first immunosuppressive treatment (MMF, MTX, CYC, tocilizumab or RTX) after SSc diagnosis, with no signs of interstitial lung disease (ILD) on high-resolution CT
- Participants
- 1,052 adults
- Exposure
- Early vs late start of first immunosuppressive treatment
- Earlyn = 547
- Outcome
- ILD-free survival and course of FVC % predicted
- Follow-up
- Up to 5 years'
Methodological detailsmulticentre (EUSTAR database and Nijmegen Systemic Sclerosis cohort), adjusted for confounders
- Multicentre (EUSTAR database and Nijmegen Systemic Sclerosis cohort)
- Adjusted for confounders
Main finding
ILD development
Hazard ratio
1.13
95% CI 0.93–1.38
Early treatmentvs Late
HR 1.13 (95% CI 0.93–1.38)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Incidence of ILD (whole cohort) · mean (s.d.) 3.6 (1.4) years
- Incidence of ILD
- 46.6%
Original publication
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis. Rheumatology (Oxford). Published 22 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →